CL2021002056A1 - Inhibidores de arginasa y métodos de uso de estos. - Google Patents
Inhibidores de arginasa y métodos de uso de estos.Info
- Publication number
- CL2021002056A1 CL2021002056A1 CL2021002056A CL2021002056A CL2021002056A1 CL 2021002056 A1 CL2021002056 A1 CL 2021002056A1 CL 2021002056 A CL2021002056 A CL 2021002056A CL 2021002056 A CL2021002056 A CL 2021002056A CL 2021002056 A1 CL2021002056 A1 CL 2021002056A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- compounds
- formula
- arginase inhibitors
- arginase
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title abstract 2
- 108700024123 Arginases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se divulgan compuestos de fórmula (Ib) o (Vc), o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden compuestos de fórmula (Ib) o (Vc) y métodos para utilizar estos para tratar el cáncer, una enfermedad inflamatoria respiratoria e inhibir la arginasa: donde R1 es -H o -C(O)CH(R1a)NHR1b; y R1a se selecciona entre -H, -alquilo (C1-C4) y CH2OR1c; R1b es -H; o como alternativa, R1a y R1b, junto con el átomo al que están unidos, forman un anillo heterocíclico de 5 miembros; y R1c es H o -CH3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802765P | 2019-02-08 | 2019-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002056A1 true CL2021002056A1 (es) | 2022-03-04 |
Family
ID=69770954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002056A CL2021002056A1 (es) | 2019-02-08 | 2021-08-04 | Inhibidores de arginasa y métodos de uso de estos. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20220106335A1 (es) |
| EP (1) | EP3921033B1 (es) |
| JP (1) | JP2022521474A (es) |
| KR (1) | KR20210126044A (es) |
| CN (1) | CN113395996B (es) |
| AU (1) | AU2020218651B2 (es) |
| BR (1) | BR112021015581A2 (es) |
| CA (1) | CA3127755A1 (es) |
| CL (1) | CL2021002056A1 (es) |
| CO (1) | CO2021011039A2 (es) |
| CR (1) | CR20210463A (es) |
| DK (1) | DK3921033T3 (es) |
| DO (1) | DOP2021000166A (es) |
| EA (1) | EA202192114A1 (es) |
| ES (1) | ES2960034T3 (es) |
| FI (1) | FI3921033T3 (es) |
| HR (1) | HRP20231092T1 (es) |
| HU (1) | HUE062968T2 (es) |
| IL (1) | IL285108B1 (es) |
| LT (1) | LT3921033T (es) |
| MA (1) | MA56324B1 (es) |
| MX (1) | MX2021009499A (es) |
| PE (1) | PE20220280A1 (es) |
| PL (1) | PL3921033T3 (es) |
| PT (1) | PT3921033T (es) |
| RS (1) | RS64781B1 (es) |
| SG (1) | SG11202108503PA (es) |
| SI (1) | SI3921033T1 (es) |
| WO (1) | WO2020161675A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| SE0300907D0 (sv) * | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Novel compounds |
| WO2010085797A2 (en) * | 2009-01-26 | 2010-07-29 | The Trustees Of University Of Pennsylvania | Arginase inhibitors and methods of use |
| EP2560978B1 (en) * | 2010-04-22 | 2019-01-30 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| EP3719024A1 (en) * | 2010-10-26 | 2020-10-07 | Mars, Incorporated | Arginase inhibitors as therapeutics |
| MX343534B (es) * | 2011-10-19 | 2016-11-09 | Mars Inc | Inhibidores de arginasa y sus aplicaciones terapeuticas. |
| MX2015007797A (es) * | 2012-12-17 | 2015-10-05 | Parion Sciences Inc | Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida. |
| PL410665A1 (pl) * | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2017175185A1 (en) * | 2016-04-08 | 2017-10-12 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
| SG10201911243WA (en) * | 2016-12-22 | 2020-02-27 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| CN108794517B (zh) * | 2017-04-27 | 2021-03-30 | 南京谷睿生物科技有限公司 | 一种精氨酸酶抑制剂及其制备方法与用途 |
| WO2019205979A1 (zh) * | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
-
2020
- 2020-02-07 ES ES20709706T patent/ES2960034T3/es active Active
- 2020-02-07 AU AU2020218651A patent/AU2020218651B2/en active Active
- 2020-02-07 US US17/429,011 patent/US20220106335A1/en active Pending
- 2020-02-07 DK DK20709706.4T patent/DK3921033T3/da active
- 2020-02-07 SI SI202030267T patent/SI3921033T1/sl unknown
- 2020-02-07 JP JP2021546232A patent/JP2022521474A/ja active Pending
- 2020-02-07 CN CN202080012567.4A patent/CN113395996B/zh active Active
- 2020-02-07 CR CR20210463A patent/CR20210463A/es unknown
- 2020-02-07 HU HUE20709706A patent/HUE062968T2/hu unknown
- 2020-02-07 SG SG11202108503PA patent/SG11202108503PA/en unknown
- 2020-02-07 WO PCT/IB2020/050982 patent/WO2020161675A1/en active Application Filing
- 2020-02-07 MX MX2021009499A patent/MX2021009499A/es unknown
- 2020-02-07 PT PT207097064T patent/PT3921033T/pt unknown
- 2020-02-07 RS RS20230898A patent/RS64781B1/sr unknown
- 2020-02-07 FI FIEP20709706.4T patent/FI3921033T3/fi active
- 2020-02-07 BR BR112021015581-3A patent/BR112021015581A2/pt unknown
- 2020-02-07 CA CA3127755A patent/CA3127755A1/en active Pending
- 2020-02-07 IL IL285108A patent/IL285108B1/en unknown
- 2020-02-07 KR KR1020217028170A patent/KR20210126044A/ko not_active Application Discontinuation
- 2020-02-07 PE PE2021001295A patent/PE20220280A1/es unknown
- 2020-02-07 HR HRP20231092TT patent/HRP20231092T1/hr unknown
- 2020-02-07 EA EA202192114A patent/EA202192114A1/ru unknown
- 2020-02-07 LT LTEPPCT/IB2020/050982T patent/LT3921033T/lt unknown
- 2020-02-07 PL PL20709706.4T patent/PL3921033T3/pl unknown
- 2020-02-07 MA MA56324A patent/MA56324B1/fr unknown
- 2020-02-07 EP EP20709706.4A patent/EP3921033B1/en active Active
-
2021
- 2021-08-04 CL CL2021002056A patent/CL2021002056A1/es unknown
- 2021-08-06 DO DO2021000166A patent/DOP2021000166A/es unknown
- 2021-08-23 CO CONC2021/0011039A patent/CO2021011039A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021009499A (es) | 2021-09-08 |
| HUE062968T2 (hu) | 2023-12-28 |
| CN113395996B (zh) | 2024-05-28 |
| BR112021015581A2 (pt) | 2021-10-05 |
| DOP2021000166A (es) | 2021-09-30 |
| IL285108B1 (en) | 2024-06-01 |
| US20220106335A1 (en) | 2022-04-07 |
| CO2021011039A2 (es) | 2021-09-09 |
| MA56324B1 (fr) | 2023-10-31 |
| CR20210463A (es) | 2021-10-15 |
| PE20220280A1 (es) | 2022-02-25 |
| CN113395996A (zh) | 2021-09-14 |
| EA202192114A1 (ru) | 2021-12-01 |
| JP2022521474A (ja) | 2022-04-08 |
| KR20210126044A (ko) | 2021-10-19 |
| SI3921033T1 (sl) | 2023-11-30 |
| SG11202108503PA (en) | 2021-09-29 |
| AU2020218651B2 (en) | 2023-01-12 |
| CA3127755A1 (en) | 2020-08-13 |
| HRP20231092T1 (hr) | 2023-12-22 |
| WO2020161675A1 (en) | 2020-08-13 |
| FI3921033T3 (fi) | 2023-09-15 |
| EP3921033A1 (en) | 2021-12-15 |
| EP3921033B1 (en) | 2023-07-26 |
| AU2020218651A1 (en) | 2021-09-30 |
| DK3921033T3 (da) | 2023-10-16 |
| IL285108A (en) | 2021-09-30 |
| PT3921033T (pt) | 2023-10-11 |
| LT3921033T (lt) | 2023-09-25 |
| ES2960034T3 (es) | 2024-02-29 |
| PL3921033T3 (pl) | 2024-01-15 |
| RS64781B1 (sr) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002096A1 (es) | Inhibidores de arginasa y sus métodos de uso. | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| CY1107221T1 (el) | Παραγωγα τριαζολιου ως ανταγωνιστες υποδοχεα ταχυκινινης | |
| CO6251294A2 (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazol4,5-b piridin-5-amina y su uso para el tratamiento del cancer | |
| AR070531A1 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| EA202092975A1 (ru) | Селективные супрессоры рецептора эстрогена | |
| PE20220705A1 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer | |
| NI200800008A (es) | Métodos para la neuroprotección | |
| UY29869A1 (es) | Compuestos de benzamida | |
| AR087212A1 (es) | ANTAGONISTAS DE CRTh2 | |
| PE20190106A1 (es) | Inhibidores del potenciador del homologo zeste 2 | |
| CO2021011039A2 (es) | Inhibidores de arginasa y métodos de uso de estos | |
| PE20220768A1 (es) | Inhibidores de molecula pequena de quinasa inductora de nf-kb | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
| PE20210404A1 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| BRPI0516112A (pt) | métodos para neuroproteção | |
| CO6180505A2 (es) | Metodos para el tratamiento de transtornos cocleares y vestibulares | |
| ECSP22054240A (es) | Compuesto y composici?n como inhibidor de quinasa del receptor pdgf | |
| EA202091886A1 (ru) | Ингибиторы аргиназы и способы их применения | |
| AR114394A1 (es) | Inhibidores de arginasa y sus métodos de uso | |
| NZ767738B2 (en) | Arginase inhibitors and methods of use thereof | |
| AR114666A1 (es) | Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer |